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RASCH ANALYSIS OF THE FATIGUE IMPACT SCALE
Meads DM1, Hampson NE1, Fisk JD2, McKenna SP1, Doward LC1,
Mayo KW3
1Galen Research, Manchester, Manchester, UK; 2Dalhousie University,
Halifax, Nova Scotia, Canada; 3Novartis Pharma AG, Basel, Basel,
Switzerland
OBJECTIVES: The Fatigue Impact Scale (FIS) is a 40-item mul-
tiple response questionnaire designed to assess fatigue, divided
into cognitive, physical, and psychosocial functioning subscales.
The purpose of the study was to improve the measure by remov-
ing differential item functioning (DIF) and reducing the number
of items. METHODS: FIS data were available from 188 patients
with multiple sclerosis (MS). These data were subjected to Rasch
analysis (one-parameter logistic item response theory) using the
RUMM programme. Fit to the Rasch model was examined via
Chi2 statistics and assessments of DIF related to gender, age and
MS type. RESULTS: FIS responses from the 188 MS patients
were analysed (47/25% male; mean age 50.9, SD 10.5; 39.6%
relapsing remitting, 36.9% primary progressive, 23.5% sec-
ondary progressive). Initial results showed that the 40-item FIS
exhibited misﬁt and was not unidimensional. Several items
exhibited DIF by age, gender or MS-type. For example, patients
aged over 50 years scored signiﬁcantly higher than patients aged
50 or younger (who had a similar level of fatigue) on the item
“I have to rely more on others to help me”. DIF by MS-type indi-
cated that answers to certain items are signiﬁcantly inﬂuenced
by the disease stage of the patient. After the removal of 9 items
that either misﬁt or exhibited age or gender DIF, the reduced FIS
ﬁt the Rasch model (Chi2 p > 0.05), providing a unidimensional
fatigue scale. The threshold map suggests that for some items the
response categories did not discriminate in the way intended,
suggesting that changing the response format may improve the
scale. CONCLUSIONS: The analysis showed that it is feasible
to derive a single unidimensional scale of fatigue from the FIS.
The severity (logit) coverage of the scale is good but there
remains item redundancy suggesting further scope for item
reduction.
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PSYCHOMETRIC PROPERTIES OF A TOUCH SCREEN
COMPUTER-BASED VERSION OF THE SF-36
Ramachandran S1,Taber T2, Coons SJ1
1University of Arizona,Tucson, AZ, USA; 2Assist Technologies,
Scottsdale, AZ, USA
OBJECTIVES: The purpose of this study was to examine the
psychometric properties of a touch screen version (Assist Tech-
nologies) of the SF-36, a widely used measure of self-reported
health status. METHODS: Non-probability purposive sampling
was used to recruit 300 subjects intended to reﬂect the primary
socio-demographic characteristics of the US general adult popu-
lation. The SF-36 was administered via touch screen along with
the EQ-5D and other items. Amount of missing data and pres-
ence of ﬂoor and ceiling effects were assessed. Scale score inter-
nal consistency was estimated using Cronbach’s alpha
coefﬁcient. As one test of construct validity, mean scale scores
were compared across groups known to differ in regard to pres-
ence of chronic conditions. Convergent and discriminant 
construct validity were evaluated through examination of corre-
lations between SF-36 scales and the EQ-5D domains.
RESULTS: A total of 312 respondents completed the study. Scale
means and standard deviations for the touch screen SF-36 in this
sample were very similar to those seen with the paper-based
format in the US general population. Less than 1% of all
responses were missing. The percentage of respondents at the
ﬂoor for almost all scales was less than 10%. Ceiling effects were
evident for several of the scales. In general, these ﬂoor and ceiling
effects were very similar to that observed in the general US pop-
ulation. All of the reliability coefﬁcients exceeded 0.70; the range
was from 0.75 to 0.93. Respondents with one or more chronic
conditions reported signiﬁcantly lower scores on all eight scales
of the SF-36 compared to those with no chronic conditions. The
direction and strength of the correlations between the SF-36
scales and the EQ-5D domains were as hypothesized. CON-
CLUSION: The comparable psychometric properties and lower
levels of missing data make this touch screen version a very
viable alternative to the paper-based SF-36 format.
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HOW LONG AGO . . . ?: ASSESSING PATIENT ADHERENCE TO
SPECIFIED QUESTIONNAIRE RECALL PERIODS
Coyne KS, Brewster-Jordan J
The MEDTAP Institute at UBC, Bethesda, MD, USA
OBJECTIVES: Patient-reported outcome (PRO) measures are
typically designed to instruct patients to consider a speciﬁc time-
frame (recall period) when answering each item. Recall periods
vary in length (i.e., 24 hours, 1 week, or 4 weeks) based upon
the condition being assessed and the objectives of the research.
The goal of this study was to assess patient adherence patterns
to recall periods varying in duration by analyzing summaries of
one-on-one qualitative patient interviews. METHODS: Data
were reviewed from eight previously conducted cognitive
debrieﬁng interviews on condition speciﬁc measures that varied
in recall period length. In all interviews, patients were speciﬁ-
cally asked what recall period they had used when completing
the PRO measure. The patient’s response and the questionnaire’s
prespeciﬁed recall period were compared. RESULTS: Cognitive
debrieﬁng data for 115 patients (55% women) with a mean age
of 57.1 was reviewed. The conditions of the ten PROs evaluated
were: GERD (n = 2), Dementia (n = 2), Diabetes (n = 3), and
Overactive Bladder (n = 3). Recall periods were: Daily (n = 1);
1 week (n = 2); 2 weeks (n = 2); 2 to 4 weeks (n = 1); and 4
weeks (n = 4). The majority of patients (57.9%) stated the recall
period speciﬁed on the PRO measure; 14.5% recalled a general
period of time (e.g. since they had the condition); 13.8% stated
a time over the recall period while 12.6% stated a time under
the recall period. Shorter recall periods (e.g. 1 week) had more
concordant patient responses than longer recall periods (80% vs.
53%). CONCLUSIONS: Patients tend to adhere better to
shorter recall periods than longer recall periods when complet-
ing PRO measures. Questionnaires with longer recall periods
often result with patients thinking in general terms of their con-
dition or using a recall period of their own.
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INDIRECT COMPARISON (OR COMMON-COMPARATOR)
METHODS FOR META-ANALYSIS OF SUMMARY DATA
Fitzgerald P, LeReun C,Aristides M
M-TAG, A division of IMS Health Economics and Outcomes
Research, London, UK
OBJECTIVES: In this presentation we summarise statistical
methods for meta-analysis when a direct comparison between
treatment effects is impossible, inadequate, or inappropriate.
METHODS: Detailed descriptions are presented, and these are
appraised per se and in relation with conventional meta-analy-
sis methods. The main methods can be summarised as follows:
weighted mean difference of relative effect measures (e.g. mean
difference, log-odds-ratio, log-relative-risk and log-hazard-ratio)
and meta-regression of relative effect measures, both of which
are based on traditional meta-analysis approaches, and weighted
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Bayesian regression models, which are more ﬂexible and are
simple to implement in freely available software. RESULTS:
Using health outcomes research examples for illustration in each
case, we describe common methodology issues arising from use
of these methods, such as when small numbers of trials are
analysed, when unequal trial sizes are included and when excess
variability between trials (or heterogeneity) is encountered.
CONCLUSIONS: For the methods considered, we offer possible
solutions, make recommendations for their use and point out sit-
uations in which caution should be exercised.
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EVALUATING THE DIFFERENCE BETWEEN AVERAGE
WHOLESALE PRICE AND WHOLESALE ACQUISITION COST
FOR PHARMACEUTICALS IN THE UNITED STATES
Malone DC, Mahmood M
University of Arizona College of Pharmacy,Tucson, AZ, USA
OBJECTIVES: 1) To examine the percent difference between
average wholesale price (AWP) and wholesale acquisition cost
(WAC) for pharmaceuticals in the United States, accounting 
for patent status and manufacturer type, and 2) to evaluate the
relationship between brand manufacturers and relabelers.
METHODS: Data for this study came from the Master Drug
Data Base (MDDB), which is a proprietary drug ﬁle containing
pricing information for all prescription and non-prescription
products available in the US. The percent difference between
AWP and WAC for prescription pharmaceuticals was compared
on a variety of facets, including single source, type of manufac-
turer (original or repackager). The difference was expressed as a
percentage of AWP (a commonly used method for reimbursing
pharmacies in the US). We also compared the AWP among brand
name manufacturers and relabelers (who repackage brand name
pharmaceuticals produced by the original manufacturer).
RESULTS: A total of 23,607 unique drug products were included
in the analysis examining AWP and WAC. The mean percent dif-
ference for brand name pharmaceuticals was 0.23 + 0.11, as
compared to 0.44 + 0.26, p < 0.001. Brand name drugs that were
available from multiple companies had a mean difference of 0.25
+ 0.14, compared to 0.20 + 0.05 for single source products (p <
0.001). The median AWP for brand name manufacturers was
$3.04 per unit, compared to $3.11 per unit for relablers. CON-
CLUSION: This study documents the magnitude of well-known
differences between AWP and WAC for brand name and generic
products. Further, branded products produced by more than one
manufacturer will have larger differences between AWP and
WAC than single source products. The ﬁndings suggest the need
for analysts to critically evaluate the use of AWP for determin-
ing product costs in the US and substantial differences exist
between single source and multiple source products. A more
transparent and accurate pricing system is needed for economic
analyses in the US.
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RELATIVE WEIGHTS ASSIGNED TO PHARMACY
PROCEDURES: OPPS METHODS DESIGN AND CONCEPTS
Baker JJ
The Resource Group, Dallas,TX, USA
OBJECTIVE: The Centers for Medicare and Medicaid Services
(CMS) assigns relative weights to procedures in the hospital out-
patient setting and may do so for pharmacy handling costs in
2006. This study examines the current approach to assignment
of relative weights for drug and biological administration codes
under the CMS Hospital Outpatient Prospective Payment System
(OPPS) and compares this approach to the resource-based level
of effort concept initially created for payment to physicians.
METHODS: Resource-based methods originally proposed for
the hospital OPPS and equivalent measurement methods in the
original Harvard RBRVS work were deconstructed and evalu-
ated. The MedPAC rationale for recommendation of relative
weights for payment of pharmacy handling costs and the pro-
posed weights were also examined and evaluated. RESULTS:
The evaluation sought indications of resource-based level of
effort applications in the OPPS and their comparability to the
original resource-based studies, especially in the area of intensity
measures. The underlying intent of the resource-based relative
value scale (RBRVS) was to create a hierarchy of resource-based
level of effort in physician service delivery. The concept of hos-
pital OPPS was also intended to reﬂect resource-based service
delivery. Procedures are assigned a relative weight, implying that
payment includes level of effort resources. Recommended 2006
handling costs for drugs are assigned ﬁve relative weights, each
compared to drawing up an injected drug for administration. We
postulate these relative weights contain insufﬁcient recognition
of the level of effort and resource consumption required, thus
distorting the concept’s initial intent. CONCLUSIONS: Many
researchers and policy makers assume that relative weights
equate to level of effort resource consumption in all instances.
We cannot ﬁnd this is so regarding the ﬁve levels of relative
weights recommended for OPPS pharmacy handling costs.
Because resource consumption is disproportionately greater than
relative weights assigned in many cases, the resulting payment
will be understated.
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ECONOMIC EVALUATION OF MEDICAL DEVICES IN FRANCE:
A CHALLENGE FOR HEALTH ECONOMISTS
Späth HM1,Taboulet F2, Carrère MO1
1GRESAC, Centre Léon Bérard, Lyon, France; 2University Toulouse 3,
Toulouse, France
OBJECTIVES: Pharmacoeconomic evaluation activities have
grown rapidly in recent years, but few economic evaluations
have focused on Medical Devices (MD). This study addresses the
barriers to conducting economic evaluations of MD, in compar-
ison with pharmacoeconomic evaluations, in order to develop a
framework for MD economic evaluation. METHODS: First, we
studied the differences between MD and drugs that possibly
impact on the completion of economic evaluations. Then, we
analysed items of the French Guidelines for Economic Evalua-
tions of Health Care Technologies developed by the “Collège des
Economistes de la Santé” [http://www.ces-asso.org/docs/France_
Guidelines_HE_Evaluation.PDF] that might be barriers to the
completion of MD economic evaluations, as compared to drugs,
and we developed suggestions to overcome these barriers.
RESULTS: In this abstract we present three of eight barriers to
performing economic evaluations of MD. The ﬁrst one relates to
the feasibility of clinical trials, e.g. inadequacy of “placebo” and
“double blinding” for MD testing and difﬁculty to include large
numbers of patients. We suggest performing comparative studies
for assessing clinical outcomes to be included in economic eval-
uations and to discuss potential bias. Secondly, MD is developed
by engineers who are used to assessing technical performance,
but not clinical and economic outcomes. We propose setting up
collaborations between engineers, health care professionals and
health economists from the very beginning of MD development.
Besides, MD effectiveness often depends on the operator (health
care professional or patient) and may change over time, when
the operator gains experience. Health economists must, there-
fore, analyse the transferability of economic evaluation results
from one setting to another and over time. CONCLUSION: We
recommend setting up multidisciplinary groups of engineers,
